hepatology

News

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan failed two phase 3 trials.

News

Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

News

Under pressure from rivals in the GLP-1 space, Novo Nordisk has been given a leg-up with a first-in-class approval for Wegovy in liver disease MASH.

News

Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.